Valneva (VALN) Q4 2025 earnings review
Lyme Binary Event Looms as U.S. IXCHIQ Ambitions Collapse
Valneva has effectively become a single-asset binary play for 2026. Despite delivering FY25 revenue of €174.7M (in line with guidance) and reducing operating cash burn to €52.9M, the commercial narrative is deteriorating rapidly. The company voluntarily withdrew its U.S. BLA for the chikungunya vaccine (IXCHIQ) following an FDA suspension, triggering massive inventory write-offs and negative gross margins for the product. Furthermore, the FDA denied approval for the new Almeida manufacturing facility to produce IXIARO for the U.S. market. With FY26 revenue guidance forecasting a deceleration (€155-170M), survival and long-term viability now rest entirely on the Phase 3 data for the Pfizer-partnered Lyme disease vaccine (VLA15) in H1 2026. Management explicitly warned that a trial failure would trigger severe restructuring.
🐂 Bull Case
Phase 3 data for VLA15 (Lyme) is expected in H1 2026. Success unlocks $143M in near-term commercialization milestones from Pfizer, 14-22% royalties, and a path to sustained profitability.
A new $500M debt facility with Pharmakon ($215M drawn to repay previous debt) pushes major maturities to 2030 and lowers the interest rate, providing crucial breathing room ahead of the Lyme readout.
🐻 Bear Case
Valneva voluntarily withdrew the U.S. BLA and IND for IXCHIQ in January 2026 following safety concerns, effectively killing its primary proprietary growth engine for the lucrative U.S. market and triggering severe inventory write-downs.
Management's own disclosures state that if the Lyme Phase 3 trial fails, the company will require immediate restructuring and renegotiation of debt, with no guarantee of survival.
⚖️ Verdict: 🔴🔴
Strongly Bearish. The withdrawal of the IXCHIQ U.S. license and FDA facility rejection strips away the downside protection of the commercial business. The stock is now entirely captive to the H1 2026 VLA15 Phase 3 readout.
Key Themes
IXCHIQ U.S. Market Exit & Margin Destruction
The narrative around IXCHIQ has completely reversed. In January 2026, Valneva voluntarily withdrew its BLA and IND in the U.S. following an FDA suspension related to adverse events. The financial damage is already visible: IXCHIQ generated just €8.4M in FY25 sales but operated at a negative gross margin, dragged down by €8.5M in inventory write-offs from the termination of the Serum Institute of India (SII) supply agreement. Total IXCHIQ inventory write-down provisions now stand at €21.6M. The company is now entirely dependent on LMICs and European travel markets for this asset.
VLA15 Lyme Readout: The Ultimate Binary Event
Everything hinges on the Phase 3 VALOR trial for VLA15, partnered with Pfizer. Data is expected in H1 2026. If approved, Valneva receives $143M in initial milestones and 14-22% royalties. However, the audited financials introduce a stark warning: if the trial fails, Valneva will 'be required to undergo restructuring' and 'renegotiation of existing debt terms' with Pharmakon to avoid default. This explicitly frames the readout as an existential event.
FDA Rejects Almeida Manufacturing Facility
In February 2026, the FDA informed Valneva it could not approve the new Almeida facility in Scotland for manufacturing IXIARO for the U.S. market due to outstanding compliance issues. While the company will revert to its Manson site for U.S. distribution, this creates inefficiencies and idle capacity costs (€10.8M recorded in FY25) at the new facility, further pressuring gross margins.
Debt Refinancing Removes Immediate Liquidity Cliff
Valneva successfully replaced its restrictive Deerfield/OrbiMed (D&O) debt with a $500M facility from Pharmakon. They drew $215M to repay the D&O loan, extending maturity from Q1 2026 to Q4 2030 and lowering the interest rate. This buys the company necessary runway to get through the 2026 clinical readouts, though the debt is secured by all intellectual property, leaving zero margin for error.
Travel Market Resiliency (Macro)
The one stable pillar remains the legacy travel vaccine portfolio. IXIARO sales grew 4.6% to €98.4M, driven by global travel market recovery and a $32.8M contract renewal with the U.S. Department of Defense. DUKORAL remained stable at €31.9M (-1.2% YoY). Excluding the planned wind-down of third-party sales, proprietary product sales grew 9% at constant exchange rates.
Shigella (S4V2) Advancing as Backup Catalyst
With IXCHIQ impaired, the Tetravalent Shigella vaccine candidate (S4V2) becomes the crucial pipeline backup. Granted FDA Fast Track designation, it targets a $500M+ annual market opportunity. Phase 2 data is expected mid-2026. If successful, Valneva will assume full development responsibility from partner LimmaTech.
Other KPIs
Reversing. Fell sharply from +€32.9M in FY24, primarily due to the absence of the €90.8M PRV sale gain that artificially boosted the prior year. The underlying business remains heavily loss-making as R&D and commercialization costs outweigh product gross profits.
Accelerating improvement (down 21% from €67.2M in FY24 and €202.7M in FY23). This reflects disciplined cost management and headcount consolidation (Nantes site closure), preserving the €109.7M cash balance.
Accelerating. Up 15% from €74.1M in FY24, driven by increased Shigella vaccine costs under the LimmaTech collaboration and IXCHIQ post-marketing obligations.
Guidance
Decelerating. Represents a decline from the €174.7M generated in FY25. The contraction is primarily driven by the planned wind-down of the low-margin third-party distribution business.
Stable to slightly Decelerating. Compares to €157.9M in FY25. Growth in proprietary products (IXIARO/DUKORAL) is being offset by the loss of third-party sales and the severely diminished expectations for IXCHIQ.
Key Questions
IXCHIQ Ex-U.S. Viability
With the voluntary withdrawal of the U.S. BLA, how materially does this reduce the peak sales expectations for IXCHIQ, and can the LMIC/European travel markets alone justify the ongoing Phase 4 and manufacturing commitments?
Almeida Remediation Timelines
The FDA cited outstanding compliance issues at the Almeida facility. What is the estimated cost and timeline for remediation, and what happens if the Manson site encounters capacity or compliance issues in the interim?
Plan B for Debt Covenants
The annual report explicitly states that a failure of the VLA15 Lyme trial would require restructuring and renegotiation with Pharmakon. What structural options (e.g., asset sales, dilution) are actively being prepared as a contingency?